[go: up one dir, main page]

MA38250B1 - Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie - Google Patents

Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie

Info

Publication number
MA38250B1
MA38250B1 MA38250A MA38250A MA38250B1 MA 38250 B1 MA38250 B1 MA 38250B1 MA 38250 A MA38250 A MA 38250A MA 38250 A MA38250 A MA 38250A MA 38250 B1 MA38250 B1 MA 38250B1
Authority
MA
Morocco
Prior art keywords
thrombocytopenia
osteoporosis
diseases
treatment
hydantoin derivatives
Prior art date
Application number
MA38250A
Other languages
English (en)
Other versions
MA38250A1 (fr
Inventor
Yoshikazu Nishimura
Toru Esaki
Tatsuya Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA38250A1 publication Critical patent/MA38250A1/fr
Publication of MA38250B1 publication Critical patent/MA38250B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé qui peut être représenté par la formule générale (1) ou un sel pharmacologiquement permis de celui-ci. (1) (dans la formule, r1, r2, r3 et r4 sont tels que définis dans les revendications.)
MA38250A 2012-12-10 2013-12-10 Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie MA38250B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012269178 2012-12-10
PCT/JP2013/083022 WO2014092061A1 (fr) 2012-12-10 2013-12-10 Dérivé d'hydantoïne

Publications (2)

Publication Number Publication Date
MA38250A1 MA38250A1 (fr) 2017-02-28
MA38250B1 true MA38250B1 (fr) 2017-10-31

Family

ID=50934349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38250A MA38250B1 (fr) 2012-12-10 2013-12-10 Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie

Country Status (35)

Country Link
US (5) US9428505B2 (fr)
EP (1) EP2930176B1 (fr)
JP (1) JP5951799B2 (fr)
KR (1) KR102168738B1 (fr)
CN (1) CN104854106B (fr)
AU (1) AU2013358167B2 (fr)
BR (1) BR112015012411B1 (fr)
CA (1) CA2892621C (fr)
CL (2) CL2015001391A1 (fr)
CR (1) CR20150272A (fr)
DK (1) DK2930176T3 (fr)
ES (1) ES2663797T3 (fr)
HK (1) HK1209735A1 (fr)
HR (1) HRP20180647T1 (fr)
HU (1) HUE037530T2 (fr)
IL (1) IL238277B (fr)
LT (1) LT2930176T (fr)
MA (1) MA38250B1 (fr)
MX (1) MX2015007309A (fr)
MY (1) MY178583A (fr)
NO (1) NO2930176T3 (fr)
NZ (1) NZ707946A (fr)
PE (1) PE20151295A1 (fr)
PH (1) PH12015501146B1 (fr)
PL (1) PL2930176T3 (fr)
PT (1) PT2930176T (fr)
RS (1) RS57190B1 (fr)
RU (1) RU2678984C2 (fr)
SA (1) SA515360528B1 (fr)
SG (1) SG11201504204XA (fr)
SI (1) SI2930176T1 (fr)
TW (1) TWI615394B (fr)
UA (1) UA115072C2 (fr)
WO (1) WO2014092061A1 (fr)
ZA (1) ZA201503597B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5671453B2 (ja) 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
SG11201504204XA (en) * 2012-12-10 2015-07-30 Chugai Pharmaceutical Co Ltd Hydantoin derivative
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
BR112021001170A2 (pt) 2018-07-30 2021-04-27 Chugai Seiyaku Kabushiki Kaisha dispersão sólida de derivado de hidantoína
CN110464002A (zh) * 2019-09-12 2019-11-19 西南石油大学 一种天然冰粉的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) * 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CA2353924A1 (fr) 1998-12-11 2000-06-22 F. Hoffmann-La Roche Ag Derives cycliques de l'hydrazine comme inhibiteurs tnf-alpha
US20050101574A1 (en) * 2000-08-30 2005-05-12 Seiichi Ishizuka Parathyroid hormone production inhibitors containing vitamin d3 derivatives
JP2004518635A (ja) * 2000-10-26 2004-06-24 ファイザー・プロダクツ・インク スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
AU2003237424A1 (en) * 2002-06-06 2003-12-22 Donnelly Corporation Interior rearview mirror system with compass
WO2005077918A1 (fr) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Agonistes de pth
EP1713815A4 (fr) * 2004-02-11 2009-03-11 Smithkline Beecham Corp Agonistes de pth
CA2582593A1 (fr) 2004-10-07 2006-04-20 Merck & Co., Inc. Antagonistes du recepteur de cgrp
WO2007135417A1 (fr) 2006-05-19 2007-11-29 James Black Foundation Dérivés de benzotriazépinone
US20070299072A1 (en) 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
ATE486058T1 (de) 2007-06-07 2010-11-15 Hoffmann La Roche Prolinamidderivate als nk3-antagonisten
WO2009074575A2 (fr) 2007-12-10 2009-06-18 Novartis Ag Composés organiques
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (fr) 2008-10-13 2010-04-22 University Of Rochester Protection et reparation de tissus mous cartilagineux et musculo-squelettiques
JP5671453B2 (ja) * 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
SG11201504204XA (en) * 2012-12-10 2015-07-30 Chugai Pharmaceutical Co Ltd Hydantoin derivative
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物

Also Published As

Publication number Publication date
KR20150092275A (ko) 2015-08-12
US20210024524A1 (en) 2021-01-28
HRP20180647T1 (hr) 2018-06-01
CA2892621A1 (fr) 2014-06-19
KR102168738B1 (ko) 2020-10-22
US20220162208A1 (en) 2022-05-26
EP2930176A4 (fr) 2016-06-01
CL2015001391A1 (es) 2015-07-31
SG11201504204XA (en) 2015-07-30
HUE037530T2 (hu) 2018-09-28
ZA201503597B (en) 2016-09-28
CL2017000069A1 (es) 2017-08-25
EP2930176A1 (fr) 2015-10-14
JP5951799B2 (ja) 2016-07-13
MY178583A (en) 2020-10-16
ES2663797T3 (es) 2018-04-17
US20180237436A1 (en) 2018-08-23
SI2930176T1 (en) 2018-06-29
CA2892621C (fr) 2021-02-16
EP2930176B1 (fr) 2018-02-07
PH12015501146B1 (en) 2017-10-27
RS57190B1 (sr) 2018-07-31
IL238277A0 (en) 2015-06-30
RU2678984C2 (ru) 2019-02-05
BR112015012411A2 (pt) 2017-07-11
CN104854106A (zh) 2015-08-19
PT2930176T (pt) 2018-04-03
JPWO2014092061A1 (ja) 2017-01-12
US20150274727A1 (en) 2015-10-01
NO2930176T3 (fr) 2018-07-07
US20160326175A1 (en) 2016-11-10
US9428505B2 (en) 2016-08-30
IL238277B (en) 2018-01-31
AU2013358167B2 (en) 2017-09-14
AU2013358167A1 (en) 2015-04-09
WO2014092061A1 (fr) 2014-06-19
BR112015012411B1 (pt) 2021-10-05
HK1209735A1 (en) 2016-04-08
SA515360528B1 (ar) 2018-05-24
CN104854106B (zh) 2017-07-04
TWI615394B (zh) 2018-02-21
TW201439092A (zh) 2014-10-16
CR20150272A (es) 2015-07-09
DK2930176T3 (en) 2018-03-19
PL2930176T3 (pl) 2018-07-31
PE20151295A1 (es) 2015-10-10
RU2015127624A (ru) 2017-01-16
LT2930176T (lt) 2018-04-10
PH12015501146A1 (en) 2015-08-10
MX2015007309A (es) 2015-09-10
NZ707946A (en) 2019-11-29
UA115072C2 (uk) 2017-09-11
MA38250A1 (fr) 2017-02-28

Similar Documents

Publication Publication Date Title
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA34797B1 (fr) Hétéroaryles et leurs utilisations
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38250B1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA38330B1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39983A (fr) Dérivés de carboxamide
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA38559B1 (fr) Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
TN2014000371A1 (fr) Dérivés macrocycliques pour le traitement de maladies prolifératives